FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 347:653-659 August 29, 2002 Number 9 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Ingelfinger, J. R. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

ABSTRACT

Background Nephrogenic adenomas are benign, tumor-like lesions within the urothelial mucosa of the urinary tract that are not uncommon in renal-transplant recipients. We investigated the origin of nephrogenic adenomas in renal-transplant recipients.

Methods Tissue sections were analyzed by fluorescence in situ hybridization with the use of probes for the X and Y chromosomes, by immunohistochemical methods with the use of antibodies to renal tubular antigens, and by lectin histochemical methods. Forty-six nephrogenic adenomas from 29 patients were analyzed.

Results All nephrogenic adenomas in 14 female recipients of transplants from male donors and 10 male recipients of transplants from female donors showed the same sex-chromosome status as the donor kidney, but not the same sex-chromosome status as the recipient's surrounding bladder tissue. The nephrogenic adenomas from all 6 female recipients of transplants from female donors showed female chromosomes, and those from the 16 male recipients of transplants from male donors showed male chromosomes. The presence of aquaporin 1, PAX2, and lectin-binding capacity for peanut agglutinin, Lotus tetragonolobus agglutinin, and Sophora japonica agglutinin in nephrogenic adenomas indicated an origin from renal tubular cells.

Conclusions Nephrogenic adenomas in renal-transplant recipients are derived from tubular cells of the renal transplants and are not metaplastic proliferations of the recipient's bladder urothelium.

Source Information

From the Department of Clinical Pathology and Center of Excellence in Clinical and Experimental Oncology (P.R.M., A.H., G.K., H.R., D.K., M.S.), the Department of Internal Medicine III (B.W.), and the Department of Urology (C.K.), University of Vienna General Hospital; and the Departments of Nephrology (R.S., F.T.M.) and Urology (R.A.-M., O.Z.), Wilhelminen Hospital — all in Vienna, Austria.

Drs. Mazal and Schaufler contributed equally to the article.

Address reprint requests to Dr. Susani at the Department of Clinical Pathology, University of Vienna General Hospital, Währinger Gürtel 18-20, A-1090 Vienna, Austria, or at martin.susani{at}akh-wien.ac.at.

Full Text of this Article

This article has been cited by other articles:

• Librez, A.S., Marie, I., Cailleux, N., Levesque, H., Francois, A., Sibert, L. (2008). Ureteral nephrogenic adenoma in antiphospholipid antibody syndrome. QJM 101: 327-329 [Full Text]  
• Mengel, M., Jonigk, D., Wilkens, L., Radermacher, J., von Wasielewski, R., Lehmann, U., Haller, H., Mihatsch, M., Kreipe, H. (2004). Chimerism of Metanephric Adenoma but Not of Carcinoma in Kidney Transplants. Am. J. Pathol. 165: 2079-2085 [Abstract] [Full Text]  
• Brophy, P. D., Lang, K. M., Dressler, G. R. (2003). The Secreted Frizzled Related Protein 2 (SFRP2) Gene Is a Target of the Pax2 Transcription Factor. J. Biol. Chem. 278: 52401-52405 [Abstract] [Full Text]  
• Ingelfinger, J. R. (2002). Nephrogenic Adenomas as Renal Tubular Outposts. NEJM 347: 684-686 [Full Text]